Deconvolution method to split up X-ray peaks emitted by 223Ra
DOI:
https://doi.org/10.15392/bjrs.v6i1.353Keywords:
X-Ray, Spectrometry, X-Ray Emission, Area Under Curve, 223Ra.Abstract
The Radium-223 (223Ra) has being used as a medicine for localized treatment of patients with osteoblastic metastasis originated by prostate cancer resistant of castration or hormone refractory. For a better treatment with this radionuclide, clinical images are one path to turn achievable organ's dosimetry for each patient. The X-rays emitted by 223Ra demonstrated as the main way to turn the image acquiring feasible. In order to study this X-ray area, deconvolution is necessary to split up the mains X-ray peaks that are measured by a high-purity germanium detector as doublet peaks in a complex region of the spectrum below 100 keV. For this, the Colegram® code was applied using the Low Energy X Voigt fitting curve on raw data source from Maestro® software. Results of activity using the deconvolution data from this work were in agreement with values obtained at absolute standardization live-time anticoincidence counting. The Colegram® code demonstrates a powerful tool to aid Maestro to split up the mains overlapped X-rays emitted by 223Ra.
Downloads
References
REFERENCES
ATKINS, H. L. Overview of nuclides for bone pain palliation. Applied radiation and isotopes, v. 49, n. 4, p. 277-283, 1998.
BELLMUNT, J. Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients. European urology, v. 63, n. 2, p. 198-200, 2013.
BRULAND, Ø. S. et al. High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra: adjuvant or alternative to conventional modalities?. Clinical cancer research, v. 12, n. 20, p. 6250s-6257s, 2006.
CHECHEV, V. P., et al. Table of radionuclides (Vol. 6–A= 22 to 242). Monographie BIPM-5, Bureau International des Poids et Mesures, Sèvres, p.85-89, 2011.
COLLINS, S. M. et al. Direct measurement of the half-life of 223Ra. Applied Radiation and Iso-topes, v. 99, p. 46-53, 2015.
DA SILVA, C. J. et al. Standardization of 241Am, 124Sb and 131I by live-timed anti-coincidence counting with extending dead time. Applied Radiation and Isotopes, v. 66, n. 6, p. 886-889, 2008.
DELGADO, J. U.; MOREL, J.; ETCHEVERRY, M. Measurements of photon emission probabili-ties from the decay of 226Ra and daughters. Applied Radiation and Isotopes, v. 56, n. 1, p. 137-143, 2002.
EMA/CHMP - European medicines Agency/Committee for Medicinal Products for Human Use, Document EMA/CHMP/411215/2013, Summary of Opinion, Initial Authorization. 19 September 2013, Available at:
<http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002653/WC500150073.pdf>. Last accessed: 15 sept. 2017.
FDA - Food and Drug Administration. FDA approves new drug for advanced prostate cancer. 2013, Available at:
<https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/203971Orig1s000ltr.pdf>
Last accessed: 15 sept. 2017.
FLUX, G. D. Imaging and dosimetry for radium-223: the potential for personalized treatment. The British Journal of Radiology, v. 90, n. 0, p. 20160748, 2017.
HENRIKSEN, G. et al. Significant antitumor effect from bone-seeking, α-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer research, v. 62, n. 11, p. 3120-3125, 2002.
KEIGHTLEY, J. et al. Standardization of 223Ra by liquid scintillation counting techniques and comparison with secondary measurements. Applied Radiation and Isotopes, v. 95, p. 114-121, 2015.
KVINNSLAND, Y.; SKRETTING, A.; BRULAND, Ø. S. Radionuclide therapy with bone-seeking compounds: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone. Physics in medicine and biology, v. 46, n. 4, p. 1149, 2001.
LÉPY, M.C. Presentation of the COLEGRAM software. Note Technique LNHB/04/26, Saclay, France, 2004.
LEWINGTON, V. J. Bone-seeking radionuclides for therapy. Journal of nuclear medicine, v. 46, n. 1 suppl, p. 38S-47S, 2005.
MADSEN, K., NIELSEN, H. B. and TINGLEFF, O. Methods for non-linear least squares prob-lems. 2004.p.24-28.
MAESTRO, I. I. Software Operator’s Manual. Maestro for Windows. Version 5.33. EG&G. ORTEC, 2002.
PACILIO, M. et al. A case report of image-based dosimetry of bone metastases with Alpharadin (223Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. Annals of nuclear medicine, v. 30, n. 2, p. 163-168, 2016.
PARKER, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, v. 369, n. 3, p. 213-223, 2013.
SÁNCHEZ-JIMÉNEZ, J. et al. 223 Ra-dichloride spectrometric characterization: Searching for the presence of long-lived isotopes with radiological protection implications. Physica Medica, v. 35, p. 97-101, 2017.
SUORTTI, P.; AHTEE, M.; UNONIUS, L. Voigt function fit of X-ray and neutron powder diffrac-tion profiles. Journal of Applied Crystallography, v. 12, n. 4, p. 365-369, 1979.
Downloads
Published
Issue
Section
License
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
